The Results of Using 5 and 10 mg Triamcinolone Acetonide in Treating Patients with De Quervain’s Disease

Treatment Results of Patients with De Quervain’s Disease

Abstract

De Quervain's disease is a common condition resulting from inflammation of the extensor pollicis brevis (EPB) and abductor pollicis longus (APL) tendons. The objective of this study was to compare the effectiveness of triamcinolone acetonide injections at doses of 5 milligrams and 10 milligrams in treating De Quervain's disease. The study utilized retrospective data from medical records and telephone follow-ups of outpatients diagnosed with De Quervain's disease at Thanyaburi Hospital from July 1, 2019 to December 31, 2023. The study involved 135 patients, with 65 receiving 5 milligrams and 70 receiving 10 milligrams of triamcinolone acetonide. After two weeks of treatment, the 10 mg and 5 mg groups had pain relief rates of 90 % and 69.2%, respectively. At four weeks, the two groups were no different, and at six weeks, the rate of pain relief was the same. Success rates favored the 10-milligram group at all-time points, with significant differences at two, four, and six months. Hypopigmentation occurred in 1.4% of the 10-milligram group. In conclusion, the study suggests that a 10-milligram dose of triamcinolone acetonide is more effective in resolving pain and ensuring success in De Quervain's disease compared to a 5-milligram dose. However, potential complications, particularly hypopigmentation require careful consideration